Breaking News Instant updates and real-time market news.

EFX

Equifax

$98.25

2.25 (2.34%)

07:09
09/22/17
09/22
07:09
09/22/17
07:09

Equifax upgraded to Outperform from Market Perform at Wells Fargo

Wells Fargo analyst William Warmington upgraded Equifax to Outperform following the 31% decline in the shares since the security breach was announced on September 7. The magnitude of the breach has created an "attractive entry point for this high-quality consumer credit franchise," Warmington tells investors in a research note. Despite the negative press, the analyst believes Equifax's core business-to-business segment will be largely unaffected from the breach. He lowered his price target for the shares to $127 from $135. Equifax closed yesterday up $2.25 to $98.25 and is trading up in the premarket another $2.45 to $100.70.

  • 22

    Oct

EFX Equifax
$98.25

2.25 (2.34%)

09/19/17
DBAB
09/19/17
NO CHANGE
Target $115
DBAB
Buy
Deutsche sees breach costing Equifax 'well below' $1B, calls selloff 'excessive'
Deutsche Bank analyst Kevin McVeigh lowered his price target for Equifax to $115 from $160 saying the shares could volatile around the congressional hearings on October 3. The analyst, however, views the $6.5B, or 35%, equity loss in a week as "excessive." He sees an $85 to $145 52-week trading range for the shares. Equifax closed yesterday up $1.40 to $94.38. Inflection in sentiment typically occurs 60-90 days post a congressional hearing before trading higher, McVeigh tells investors in a research note titled "Charting unchartered territory." He believes the total impact of the breach, not adjusting for insurance or other offsets, should be "well below" $1B. The analyst keeps a Buy rating on Equifax shares.
09/18/17
OPCO
09/18/17
NO CHANGE
Target $45
OPCO
Outperform
Equifax breach could become tailwind for Fortinet, says Oppenheimer
Following a meeting with Fortinet's (FTNT) management, Oppenheimer analyst Shaul Eyal believes the Equifax (EFX) breach could yield an effect akin to the late-2013 Target (TGT) breach, whereby heightened security awareness and an increase in involvement across boards and C-level executives which could convert into increased security budgets. Further, the analyst believes Fortinet is focused on better positioning itself for IT trends, and that its "strong growth" in subscription services remains in-tact and higher-end appliance traction remains a strong-point for its product segment. Eyal reiterates an Outperform rating and $45 price target on Fortinet's shares.
09/15/17
09/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Equifax (EFX) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing news of a major hack on the company's data that could have lasting effects. 2. FedEx (FDX) downgraded to Neutral from Buy at UBS with analyst Thomas Wadewitz citing TNT issues following the cyber-attack in June that knocked out multiple systems. 3. Carnival (CCL) downgraded to Neutral from Outperform at Credit Suisse with analyst Tim Ramskil saying he is worried that his estimate of absolute industry capacity growth in 2018-2021 is double that of the last five years. 4. American Airlines (AAL), United Continental (UAL), and Spirit Airlines (SAVE) were downgraded to Neutral from Overweight at JPMorgan. 5. Acuity Brands (AYI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Richard Kwas saying his firm's electrical channel checks indicate the 8% consensus organic revenue growth estimate for FY18 does not have upside. The analyst thinks shares are likely range-bound in the $160-$200 range "for the time being." He believes a "material step up" in tiered solutions growth is needed for gross margin to outperform expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/17
BARD
09/15/17
NO CHANGE
Target $115
BARD
Outperform
Equifax price target lowered to $115 from $141 at Baird
Baird analyst Jeffrey Mueler lowered his price target on Equifax to $115 from $141 as he reduced his Global Consumer revenue estimate while assuming tougher U.S. B2B new sales and cross-sales and some volume share loss. He is also assuming increased expenses and removing share repurchases from his estimates. Mueler maintained his Outperform rating on Equifax shares.

TODAY'S FREE FLY STORIES

AJRD

Aerojet Rocketdyne

$34.40

0.51 (1.50%)

05:44
10/23/17
10/23
05:44
10/23/17
05:44
Downgrade
Aerojet Rocketdyne rating change  »

Aerojet Rocketdyne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:30
10/23/17
10/23
05:30
10/23/17
05:30
General news
FX Action: USD-JPY has remained settled under 114.00 »

FX Action: USD-JPY has…

NVS

Novartis

$85.74

-0.42 (-0.49%)

05:29
10/23/17
10/23
05:29
10/23/17
05:29
Hot Stocks
Novartis receives FDA Breakthrough Therapy Designation for Tafinlar/Mekinist »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 17

    May

BA

Boeing

$264.75

5.71 (2.20%)

05:25
10/23/17
10/23
05:25
10/23/17
05:25
Hot Stocks
Boeing, Mitsubishi Heavy reach agreement on cost reduction for 787 production »

Boeing and Mitsubishi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BAC

Bank of America

$27.17

0.59 (2.22%)

05:24
10/23/17
10/23
05:24
10/23/17
05:24
Hot Stocks
Merrill Lynch fined $45.5M in Britain for not reporting derivative transactions »

Bank of America's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ATHN

athenahealth

$126.04

9.63 (8.27%)

05:18
10/23/17
10/23
05:18
10/23/17
05:18
Upgrade
athenahealth rating change  »

athenahealth upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$33.23

-0.835 (-2.45%)

05:13
10/23/17
10/23
05:13
10/23/17
05:13
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$48.37

0.24 (0.50%)

05:12
10/23/17
10/23
05:12
10/23/17
05:12
Downgrade
Rio Tinto rating change  »

Rio Tinto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELI

MercadoLibre

$235.73

-0.27 (-0.11%)

05:02
10/23/17
10/23
05:02
10/23/17
05:02
Recommendations
MercadoLibre analyst commentary  »

MercadoLibre price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$338.10

-4.32 (-1.26%)

04:59
10/23/17
10/23
04:59
10/23/17
04:59
Initiation
Biogen initiated  »

Biogen assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CELG

Celgene

$121.33

-14.63 (-10.76%)

04:56
10/23/17
10/23
04:56
10/23/17
04:56
Downgrade
Celgene rating change  »

Celgene assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

ASOMY

ASOS

$74.28

1.5 (2.06%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
ASOS management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

PAY

Verifone

$20.06

0.06 (0.30%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Verifone management to meet with Jefferies »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 14

    Dec

PLUG

Plug Power

$2.70

0.17 (6.72%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Plug Power to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 16

    Nov

DDAIF

Daimler AG

$80.57

-1.11 (-1.36%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Daimler AG management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

September Chicago Fed…

IVC

Invacare

$14.60

0.05 (0.34%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Invacare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALXN

Alexion

$139.02

-1.44 (-1.03%)

04:54
10/23/17
10/23
04:54
10/23/17
04:54
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 06

    Nov

BIVV

Bioverativ

$60.22

0.49 (0.82%)

04:52
10/23/17
10/23
04:52
10/23/17
04:52
Initiation
Bioverativ initiated  »

Bioverativ assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 06

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

04:50
10/23/17
10/23
04:50
10/23/17
04:50
Downgrade
Tesaro rating change  »

Tesaro assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

AMAG

Amag Pharmaceuticals

$15.60

-0.45 (-2.80%)

04:48
10/23/17
10/23
04:48
10/23/17
04:48
Initiation
Amag Pharmaceuticals initiated  »

Amag Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 02

    Feb

  • 14

    Feb

04:15
10/23/17
10/23
04:15
10/23/17
04:15
General news
FX Action: USD-CAD has remained underpinned »

FX Action: USD-CAD has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.